The gene editing industry has entered a new era. With the first CRISPR-based therapy now approved and generating revenue, the question is no longer whether gene editing will transform medicine but which companies will lead the charge. Here are the CRISPR companies investors and scientists should be watching closely in 2026.
CRISPR Therapeutics: First to Market
CRISPR Therapeutics (CRSP) holds the distinction of co-developing the first FDA-approved CRISPR therapy. Casgevy, its groundbreaking treatment for sickle cell disease and transfusion-dependent beta-thalassemia developed in partnership with Vertex Pharmaceuticals, reached the market in late 2023. By 2026, the company is focused on scaling commercial delivery of Casgevy while expanding its pipeline.
Beyond hemoglobinopathies, CRISPR Therapeutics has been advancing its immuno-oncology portfolio, including allogeneic CAR-T cell therapies that use CRISPR editing to create "off-the-shelf" cancer treatments. The company's CTX110 and CTX130 programs target B-cell malignancies and solid tumors, respectively. Their in vivo gene editing programs for cardiovascular and autoimmune diseases also represent the next frontier for the company.
Market position: Strong revenue from Casgevy, diversified pipeline, significant cash reserves.
Intellia Therapeutics: The In Vivo Pioneer
Intellia Therapeutics (NTLA) has positioned itself as the leader in in vivo CRISPR gene editing, meaning it delivers gene editing tools directly into the body rather than editing cells outside the body and reinfusing them. This approach could dramatically expand which diseases CRISPR can treat.
The company's lead program, NTLA-2001, targets transthyretin amyloidosis (ATTR), a progressive and often fatal disease caused by misfolded TTR protein. Clinical data has shown remarkable reductions in serum TTR levels following a single infusion. Intellia's second program, NTLA-2002, targets hereditary angioedema by editing the KLKB1 gene in the liver.
What sets Intellia apart is its proprietary lipid nanoparticle (LNP) delivery system, which enables systemic delivery of CRISPR-Cas9 components to the liver and potentially other organs. The company is also developing next-generation editing approaches including gene insertion and epigenetic editing.
Market position: Clinical-stage leader in in vivo editing, strong intellectual property, potential for first-in-class approvals.
Beam Therapeutics: Precision Base Editing
Beam Therapeutics (BEAM) is built on base editing technology developed by David Liu at the Broad Institute. Unlike traditional CRISPR, which cuts both strands of DNA, base editors chemically convert one DNA letter to another without making double-strand breaks. This precision approach reduces the risk of unwanted insertions, deletions, and chromosomal rearrangements.
Beam's lead program, BEAM-101, targets sickle cell disease by making a single base change that reactivates fetal hemoglobin production. The company is also advancing programs in alpha-1 antitrypsin deficiency, glycogen storage disease, and T-cell acute lymphoblastic leukemia. Beam's multiplex base editing approach for oncology, which makes several simultaneous edits to create enhanced CAR-T cells, is particularly compelling.
Market position: Differentiated technology platform, broad pipeline, expanding manufacturing capabilities.
Editas Medicine: CRISPR Pioneer Evolving
Editas Medicine (EDIT) was one of the first CRISPR companies founded, with intellectual property licensed from the Broad Institute based on Feng Zhang's work. The company has had a turbulent journey, including leadership changes and pipeline shifts, but remains a significant player.
Editas is developing EDIT-101 for Leber congenital amaurosis type 10 (LCA10), a form of inherited blindness. This in vivo approach delivers CRISPR directly to photoreceptor cells in the retina. The company has also been building its ex vivo editing platform for hematologic diseases and is exploring next-generation Cas12-based editors.
Market position: Strong IP portfolio, in vivo ocular editing expertise, undergoing strategic refocusing.
Caribou Biosciences: The chRDNA Advantage
Caribou Biosciences (CRBU), co-founded by Jennifer Doudna, has developed a proprietary approach using chemically modified guide RNAs called chRDNAs (CRISPR hybrid RNA-DNA guides). These hybrid guides improve the precision of genome editing by reducing off-target effects.
The company's pipeline is focused on allogeneic cell therapies for hematologic malignancies. CB-010, its lead program for relapsed or refractory B-cell non-Hodgkin lymphoma, uses chRDNA-based editing to create next-generation CAR-T cells. Caribou's approach includes knocking out PD-1 on the CAR-T cells to enhance their anti-tumor activity.
Market position: Differentiated guide RNA technology, focused oncology pipeline, strong scientific founding team.
Prime Medicine: Search-and-Replace Editing
Prime Medicine (PRME) is commercializing prime editing, another invention from David Liu's lab. Prime editing has been described as a "search-and-replace" tool for the genome. It can make all 12 types of point mutations, as well as small insertions and deletions, without requiring double-strand breaks or donor DNA templates.
The company is developing therapies for chronic granulomatous disease, alpha-1 antitrypsin deficiency, and several other genetic conditions. Prime Medicine's key challenge is optimizing delivery efficiency, as prime editors are larger molecular complexes than standard CRISPR-Cas9. However, the precision and versatility of the technology make it one of the most promising long-term platforms in gene editing.
Market position: Most versatile editing technology, early-stage pipeline, significant IP moat.
Verve Therapeutics: Editing for Heart Disease
Verve Therapeutics (VERV) is taking a bold approach by applying gene editing to the most common cause of death worldwide: cardiovascular disease. The company's lead program, VERVE-101, uses base editing delivered via lipid nanoparticles to inactivate the PCSK9 gene in the liver, permanently lowering LDL cholesterol with a single infusion.
The idea is revolutionary: rather than treating heart disease with daily pills for decades, a one-time gene editing treatment could provide lifelong protection. Verve is also developing programs targeting ANGPTL3 for patients with elevated triglycerides.
Clinical development has shown promising early results, though safety monitoring remains critical given the target patient population. If successful, Verve's approach could redefine preventive cardiology and represent the largest addressable market for any gene editing therapy.
Market position: Largest potential market, bold clinical vision, first-mover advantage in cardiovascular gene editing.
The Competitive Landscape in 2026
The CRISPR industry has matured significantly. Several trends define the current landscape:
- Delivery innovation is the key differentiator. Companies with proprietary LNP or AAV delivery systems have a competitive edge in reaching tissues beyond the liver and blood.
- Next-generation editors like base editing and prime editing are challenging traditional CRISPR-Cas9, offering greater precision for specific applications.
- Manufacturing scale-up remains a bottleneck, particularly for ex vivo cell therapies that require patient-specific or donor-derived cells.
- Regulatory pathways are becoming clearer as agencies gain experience evaluating gene editing therapies.
- Reimbursement models for one-time curative therapies continue to evolve, with outcomes-based payment arrangements gaining traction.
Looking Ahead
The gene editing sector in 2026 is no longer defined by a single breakthrough but by a wave of clinical programs advancing across multiple diseases. From sickle cell to heart disease, from cancer to inherited blindness, CRISPR-based companies are tackling conditions that were previously considered untreatable.
For investors, the key metrics to watch are clinical trial readouts, regulatory milestones, and commercial execution for approved therapies. For patients, the promise of gene editing is becoming a reality, one company at a time.
The revolution is not coming. It is already here.
